Ganaxolone
Last Updated: 02/24/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 219 publications
Ganaxolone, an approved therapy for CDKL5-Deficiency Disorder, is an inhibitor of PTP1B.
Journal: bioRxiv : the preprint server for biology
Published: November 24, 2025
Molecular mechanisms of neurosteroids in temporal lobe epilepsy: current insights and therapeutic perspectives.
Journal: Molecular biology reports
Published: August 26, 2025
Perampanel, Brivaracetam, Cenobamate, Stiripentol, and Ganaxolone in Lennox-Gastaut Syndrome: A Comprehensive Narrative Review.
Journal: Journal of clinical medicine
Published: July 31, 2025
Peripartum Depression Pharmacotherapies Targeting GABA-Glutamate Neurotransmission.
Journal: Journal of clinical medicine
Published: July 31, 2025
Ganaxolone in Epilepsy: Insights into a Neurosteroid-Based Therapy.
Journal: Epilepsy research
Published: June 30, 2025
Tough to treat: What we know about managing PCDH19-related epilepsy - Systematic review.
Journal: Seizure
Published: June 30, 2025
Recent Advances in the Management of Seizures in Children.
Journal: Paediatric drugs
Published: June 29, 2025
Brexanolone, zuranolone and related neurosteroid GABAA receptor positive allosteric modulators for postnatal depression.
Journal: The Cochrane database of systematic reviews
Published: June 25, 2025
Therapeutic Potential of Enzymes, Neurosteroids, and Synthetic Steroids in Neurodegenerative Disorders: A Critical Review.
Journal: The Journal of steroid biochemistry and molecular biology
Published: March 10, 2025
Update on neonatal and infantile onset epilepsies.
Journal: Current opinion in pediatrics
Published: February 11, 2025
Successful Treatment of Cryptogenic NORSE Resistant to Immunosuppression With Intravenous Ganaxolone and Electroconvulsive Therapy.
Journal: The Neurohospitalist
Published: February 09, 2025
Update on Antiseizure Medications 2025.
Journal: Continuum (Minneapolis, Minn.)
Published: February 03, 2025
Last Updated: 02/24/2026